BNP Paribas Financial Markets Buys 364,801 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Posted by George Bondi on Jun 9th, 2026

BNP Paribas Financial Markets grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 107.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 703,664 shares of the company’s stock after purchasing an additional 364,801 shares during the quarter. BNP Paribas Financial Markets’ holdings in Amneal Pharmaceuticals were worth $8,866,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Spire Wealth Management grew its stake in shares of Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Intech Investment Management LLC grew its stake in shares of Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after purchasing an additional 1,159 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the period. Comerica Bank grew its stake in shares of Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the period. Finally, CWM LLC grew its stake in shares of Amneal Pharmaceuticals by 9.7% during the fourth quarter. CWM LLC now owns 32,070 shares of the company’s stock worth $404,000 after purchasing an additional 2,840 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMRX has been the subject of a number of recent analyst reports. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.80.

Check Out Our Latest Analysis on Amneal Pharmaceuticals

Amneal Pharmaceuticals Trading Down 0.3%

AMRX stock opened at $13.71 on Tuesday. The stock has a 50-day moving average price of $12.76 and a two-hundred day moving average price of $12.99. The stock has a market cap of $4.37 billion, a PE ratio of 36.08 and a beta of 1.30. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.53 and a 1 year high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 17.30% of the company’s stock.

About Amneal Pharmaceuticals

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.